Cargando…

Polyglutamine Ataxias: Our Current Molecular Understanding and What the Future Holds for Antisense Therapies

Polyglutamine (polyQ) ataxias are a heterogenous group of neurological disorders all caused by an expanded CAG trinucleotide repeat located in the coding region of each unique causative gene. To date, polyQ ataxias encompass six disorders: spinocerebellar ataxia types 1, 2, 3, 6, 7, and 17 and accou...

Descripción completa

Detalles Bibliográficos
Autores principales:	McIntosh, Craig S., Li, Dunhui, Wilton, Steve D., Aung-Htut, May T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615177/ https://www.ncbi.nlm.nih.gov/pubmed/34829728 http://dx.doi.org/10.3390/biomedicines9111499

Ejemplares similares

Removal of the Polyglutamine Repeat of Ataxin-3 by Redirecting pre-mRNA Processing
por: McIntosh, Craig S., et al.
Publicado: (2019)

Correction to: Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies
por: Li, Dunhui, et al.
Publicado: (2021)

Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies
por: Li, Dunhui, et al.
Publicado: (2021)

Systematic Approach to Developing Splice Modulating Antisense Oligonucleotides
por: Aung-Htut, May T., et al.
Publicado: (2019)

Induction of cryptic pre-mRNA splice-switching by antisense oligonucleotides
por: Ham, Kristin A., et al.
Publicado: (2021)

Induced alternative splicing an opportunity to study PCSK9 protein isoforms at physiologically relevant concentrations
por: Cale, Jessica M., et al.
Publicado: (2023)

Splice correction therapies for familial hypercholesterolemic patients with low-density lipoprotein receptor mutations
por: McIntosh, Craig S., et al.
Publicado: (2021)

Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice
por: Toonen, Lodewijk J.A., et al.
Publicado: (2017)

In Vitro Validation of Phosphorodiamidate Morpholino Oligomers
por: Aung-Htut, May T., et al.
Publicado: (2019)

A Splice Intervention Therapy for Autosomal Recessive Juvenile Parkinson’s Disease Arising from Parkin Mutations
por: Li, Dunhui, et al.
Publicado: (2020)

Nonsequential Splicing Events Alter Antisense-Mediated Exon Skipping Outcome in COL7A1
por: Ham, Kristin A., et al.
Publicado: (2020)

Reduction of integrin alpha 4 activity through splice modulating antisense oligonucleotides
por: Aung-Htut, May T., et al.
Publicado: (2019)

Consequences of Making the Inactive Active Through Changes in Antisense Oligonucleotide Chemistries
por: Zaw, Khine, et al.
Publicado: (2019)

The Mechanisms of Nuclear Proteotoxicity in Polyglutamine Spinocerebellar Ataxias
por: Lee, Davin, et al.
Publicado: (2020)

Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias
por: Buijsen, Ronald A.M., et al.
Publicado: (2019)

Functional implications of paralog genes in polyglutamine spinocerebellar ataxias
por: Felício, Daniela, et al.
Publicado: (2023)

Splice modulating antisense oligonucleotides restore some acid-alpha-glucosidase activity in cells derived from patients with late-onset Pompe disease
por: Aung-Htut, May Thandar, et al.
Publicado: (2020)

Targeted Molecular Therapeutics for Parkinson's Disease: A Role for Antisense Oligonucleotides?
por: Li, Dunhui, et al.
Publicado: (2022)

Gene Deregulation and Underlying Mechanisms in Spinocerebellar Ataxias With Polyglutamine Expansion
por: Niewiadomska-Cimicka, Anna, et al.
Publicado: (2020)

Current Status of Gene Therapy Research in Polyglutamine Spinocerebellar Ataxias
por: Afonso-Reis, Ricardo, et al.
Publicado: (2021)

Myelinating Glia: Potential Therapeutic Targets in Polyglutamine Spinocerebellar Ataxias
por: Putka, Alexandra F., et al.
Publicado: (2023)

What the future holds for gliptins
por: Jindal, Radhika, et al.
Publicado: (2012)

What does the future hold?
por: de Campos, Fernando Peixoto Ferraz
Publicado: (2012)

Cardiac surgery: What the future holds?
por: Parissis, Haralabos
Publicado: (2011)

Thyromimetics: What does the future hold?
por: Unnikrishnan, A. G., et al.
Publicado: (2012)

Ophthalmic Manifestations and Genetics of the Polyglutamine Autosomal Dominant Spinocerebellar Ataxias: A Review
por: Park, Jun Young, et al.
Publicado: (2020)

Cognitive Changes in the Spinocerebellar Ataxias Due to Expanded Polyglutamine Tracts: A Survey of the Literature
por: Lindsay, Evelyn, et al.
Publicado: (2017)

Diabetic nephropathy: What does the future hold?
por: Montero, R. M., et al.
Publicado: (2015)

What the future holds for Biomedical Engineering Online?
por: Sejdić, Ervin, et al.
Publicado: (2019)

450 Years—What Does the Future Hold?
por: Rosenheim, Max
Publicado: (1968)

What does the future hold for the workforce of tomorrow?
por: Westgarth, David
Publicado: (2020)

What does the future hold for clinical microbiology?
por: Raoult, Didier, et al.
Publicado: (2004)

Therapy for SIAD: what does the future hold?
por: Tzoulis, Ploutarchos
Publicado: (2023)

Hold up Our Hands
Publicado: (1885)

How to Hold Our Husbands
Publicado: (1913)

Urine levels of the polyglutamine ataxin-3 protein are elevated in patients with spinocerebellar ataxia type 3
por: Koike, Yuka, et al.
Publicado: (2021)

New Perspectives of Gene Therapy on Polyglutamine Spinocerebellar Ataxias: From Molecular Targets to Novel Nanovectors
por: Borbolla-Jiménez, Fabiola V., et al.
Publicado: (2021)

Spermatogonial stem cells: What does the future hold?
por: Tournaye, H., et al.
Publicado: (2011)

What will the future hold: RNP quality control and degradation
por: Karbstein, Katrin
Publicado: (2015)

Treatment of Axial Spondyloarthritis: What Does the Future Hold?
por: Poddubnyy, Denis, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ge49hn70qpnjn7fcs6nukv9a56